References
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Eng J Med 1993; 329: 987–994
- Marcus R. Current treatment options in aggressive lymphoma. Leuk Lymphoma 2003; 44(Suppl 4)S15–S27
- Phekoo K J, Schey S A, Richards M A, Bevan D H, Bell S, Gillett D, Moller H. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299–304
- Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363: 875–887
- Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533–539
- Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253
- Leger C S, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204–210
- Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timofeeva I, Bertuzzi A, et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Am J Hematol 2003; 73: 267–272
- Villela L, Sureda A, Canals C, Sanz M A, Jr, Martino R, Valcarcel D, et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300–305
- Reece D E, Bredeson C, Perez W S, Jagannath S, Zhang M J, Ballen K K, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs. ⩾60 years of age. Bone Marrow Transplant 2003; 32: 1135–1143
- Siegel D S, Desikan K R, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51–54
- Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607
- de la Rubia J, Saavedra S, Sanz G F, Martin G, Moscardo F, Martinez J, et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21–25
- Jantunen E, Mahlamaki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (⩾60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 2000; 26: 737–741
- Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp M J, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant 1998; 21: 1193–1196
- Gopal A K, Gooley T A, Golden J B, Maloney D G, Bensinger W I, Petersdorf S H, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599
- Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001; 27: 1189–1195
- Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D, Tilly H. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31–35
- Bitran J D, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388
- Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005; 19: 7–12